SCHEMBL14865645

SCHEMBL14865645

COCC(CO)CNCc1ccc(-c2cc(-c3cncc(-c4ccnc(C(C)(C)C#N)c4)n3)on2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 4/20 0.35
CYP3A4 P08684 4/20 0.35
CYP2C9 P11712 3/20 0.35
CYP1A2 P05177 2/20 0.35
ATR Q13535 10/20 0.35
ATM Q13315 3/20 0.35
PRKDC P78527 2/20 0.35
JAK2 O60674 1/20 0.34
ABL1 P00519 1/20 0.34
KIT P10721 1/20 0.34
SERPINA2 P20848 1/20 0.34
PIK3R1 P27986 1/20 0.34
FLT4 P35916 1/20 0.34
FLT3 P36888 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
SYK P43405 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
MAP3K9 P80192 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14866710 0.89 ATR (0.49) ATRATMPRKDCJAK2ABL1
SCHEMBL14865627 0.84 ATR (0.45) CYP2C19CYP3A4CYP2C9CYP1A2ATR
SCHEMBL14865770 0.83 S1PR1 (0.39) CYP2C19CYP3A4CYP2C9CYP1A2ATR
SCHEMBL14865762 0.82 PRKD1 (0.37) CYP2C19CYP3A4CYP2C9CYP1A2ATR
SCHEMBL14865636 0.81 PRKD1 (0.46) CYP2C19CYP3A4CYP2C9CYP1A2ATR
SCHEMBL14865613 0.80 PRKD1 (0.43) CYP2C19CYP3A4CYP2C9CYP1A2ATR
SCHEMBL14865681 0.79 CYP3A4 (0.37) CYP2C19CYP3A4CYP2C9CYP1A2ATR
SCHEMBL14865650 0.79 HSD17B1 (0.38) CYP2C19CYP3A4CYP2C9CYP1A2RAF1
SCHEMBL14865695 0.79 PRKD1 (0.52) CYP2C19CYP3A4CYP2C9CYP1A2ATR
SCHEMBL14865823 0.78 PRKD1 (0.48) CYP2C19CYP3A4CYP2C9CYP1A2ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130095193-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130095193-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 CYP2C19 4667/4885CYP3A4 4509/4885CYP2C9 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.